argenx (ARGX) is trading down at $925.70 (-1.73%) on NASDAQ, as of the latest quote. It operates in the Health Care sector.
Current price targets from 3 firms average $1.09k, median $1.2k, ranging from $861 to $1.2k — the average is 17% above the current $926. Each is tracked to its date and scored the same way a member's call is.
3 targets, newest first. Open a row for its source and scoring.
Entry price $876, the close nearest Oct 22, 2026, when the target was reported; the target is -2% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.
Scoring Open: judged on the close on Oct 22, 2027.
Baird raised its price target on argenx SE (NASDAQ:ARGX) to $861 from $823 while maintaining a Neutral rating on the stock.
Entry price $876, the close nearest Oct 22, 2026, when the target was reported; the target is +37% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.
Scoring Open: judged on the close on Oct 22, 2027.
Jefferies reiterated a Buy rating and $1,200 price target on argenx SE
Entry price $876, the close nearest Oct 22, 2026, when the target was reported; the target is +37% from it.
Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.
Scoring Open: judged on the close on Oct 22, 2027.
Stifel lowered its price target on argenx SE (NASDAQ:ARGX) to $1,200 from $1,282 while maintaining a Buy rating on the stock.
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $78.5M | $41.2M | $497.3M | $410.7M | $1.23B | $2.19B | $4.15B |
| Growth (year over year) | — | −47.4% | +1105.7% | −17.4% | +198.6% | +78.6% | +89.6% |
| Gross profit | — | — | — | $381.3M | $1.11B | $1.96B | $3.70B |
| Gross margin | — | — | — | 92.8% | 90.4% | 89.6% | 89.1% |
| Operating income | −$198.9M | −$477.6M | −$348.7M | −$720.3M | −$425.0M | −$21.7M | $1.05B |
| Operating margin | −253.5% | −1158.1% | −70.1% | −175.4% | −34.7% | −1.0% | 25.4% |
| Net income | −$181.2M | −$608.5M | −$408.3M | −$709.6M | −$295.1M | $833.0M | $1.29B |
| Net margin | −231.0% | −1475.3% | −82.1% | −172.8% | −24.1% | 38.0% | 31.1% |
| EPS (diluted) | −$4.69 | −$13.40 | −$7.99 | −$13.05 | −$5.16 | $12.78 | $19.57 |
| Balance sheet | |||||||
| Cash and equivalents | $372.2M | $1.22B | $1.33B | $800.7M | $2.05B | $1.50B | $3.49B |
| Total assets | $1.61B | $2.28B | $2.85B | $3.13B | $4.54B | $6.20B | $8.68B |
| Total liabilities | $429.8M | $605.4M | $316.1M | $320.6M | $445.0M | $704.2M | $1.36B |
| Shareholders' equity | $1.18B | $1.67B | $2.53B | $2.81B | $4.10B | $5.50B | $7.32B |
| Cash flow | |||||||
| Operating cash flow | $151.6M | −$398.5M | −$606.8M | −$862.8M | −$420.3M | −$82.7M | $685.2M |
| Capital expenditure | $1.80M | $1.07M | $3.62M | $837.0K | $812.0K | $1.80M | $6.17M |
| Free cash flow | $149.8M | −$399.5M | −$610.4M | −$863.6M | −$421.1M | −$84.5M | $679.0M |
| Q1 FY22†Mar 2022 | Q2 FY22Jun 2022 | Q4 FY22Dec 2022 | |
|---|---|---|---|
| Income statement | |||
| Revenue | $2.61M | $96.0M | — |
| Balance sheet | |||
| Cash and equivalents | — | $1.37B | $800.7M |
| Total assets | — | $3.25B | $3.13B |
| Total liabilities | — | $279.0M | $320.6M |
| Shareholders' equity | — | $2.97B | $2.81B |
From argenx's 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Read at Investing.com ↗ Link to this story
Read at Investing.com ↗ Link to this story
Read at Investing.com ↗ Link to this story
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs.